- Alzamend Neuro ( NASDAQ: ALZN ) said on Wednesday that it expects topline data from a Phase IIA trial for AL001 treatment of dementia related to Alzheimer’s in second quarter of 2023.
- The company also said it was partnering with the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for its Phase I/IIA clinical trial its cell-based therapeutic vaccine, ALZN002, to treat Alzheimer's.
- The company expects to begin this study in the first quarter of 2023.
- Alzamend said it had begun dosing healthy people in a phase 2A study of oral drug AL001 treat people with dementia related to Alzheimer’s in October .
- ( ALZN ) is up 2.3% before the bell.
For further details see:
Alzamend to post mid-stage trial data from Alzheimer's treatment in Q2